Epithelial Membrane Protein-2 in Human Proliferative Vitreoretinopathy and Epiretinal Membranes

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2016 Jun 14

PMID 27294805

Citations 10

Authors

David G Telander

Alfred K Yu

Krisztina I Forward

Shawn A Morales

Lawrence S Morse

Susanna S Park

Lynn K Gordon

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine the level of epithelial membrane protein-2 (EMP2) expression in preretinal membranes from surgical patients with proliferative vitreoretinopathy (PVR) or epiretinal membranes (ERMs). EMP2, an integrin regulator, is expressed in the retinal pigment epithelium and understanding EMP2 expression in human retinal disease may help determine whether EMP2 is a potential therapeutic target.

Methods: Preretinal membranes were collected during surgical vitrectomies after obtaining consents. The membranes were fixed, processed, sectioned, and protein expression of EMP2 was evaluated by immunohistochemistry. The staining intensity (SI) and percentage of positive cells (PP) in membranes were compared by masked observers. Membranes were categorized by their cause and type including inflammatory and traumatic.

Results: All of the membranes stained positive for EMP2. Proliferative vitreoretinopathy-induced membranes (all causes) showed greater expression of EMP2 than ERMs with higher SI (1.81 vs. 1.38; P = 0.07) and PP (2.08 vs. 1.54; P = 0.09). However all the PVR subgroups had similar levels of EMP2 expression without statistically significant differences by Kruskal-Wallis test. Inflammatory PVR had higher expression of EMP2 than ERMs (SI of 2.58 vs. 1.38); however, this was not statistically significant. No correlation was found between duration of PVR membrane and EMP2 expression. EMP2 was detected by RT-PCR in all samples (n = 6) tested.

Conclusions: All studied ERMs and PVR membranes express EMP2. Levels of EMP2 trended higher in all PVR subgroups than in ERMs, especially in inflammatory and traumatic PVR. Future studies are needed to determine the role of EMP2 in the pathogenesis and treatment of various retinal conditions including PVR.

Citing Articles

Fibrotic Changes in Rhegmatogenous Retinal Detachment.

Harju N, Kauppinen A, Loukovaara S Int J Mol Sci. 2025; 26(3).

PMID: 39940795 PMC: 11817287. DOI: 10.3390/ijms26031025.

Predictive factors of epiretinal membrane in complicated rhegmatogenous retinal detachment tamponaded with silicone oil.

Qian Y, Xiang W, Sun Y, Mijit A, Jiang Z, Wei Y Int J Ophthalmol. 2023; 16(7):1110-1116.

PMID: 37465504 PMC: 10333257. DOI: 10.18240/ijo.2023.07.16.

Network-based inference of master regulators in epithelial membrane protein 2-treated human RPE cells.

Wan H, Gao W, Zhang W, Tao Z, Lu X, Chen F BMC Genom Data. 2022; 23(1):52.

PMID: 35799115 PMC: 9264685. DOI: 10.1186/s12863-022-01047-9.

Internal Limiting Membrane Peeling versus Nonpeeling to Prevent Epiretinal Membrane Formation following Vitrectomy for Posterior Segment Open-Globe Injury.

Wei W, Lin Z, Xu M, Feng K, Zhao Z J Ophthalmol. 2021; 2021:3152728.

PMID: 34497723 PMC: 8419486. DOI: 10.1155/2021/3152728.

[Proliferative vitreoretinopathy prophylaxis : Mission (im)possible].

Schaub F, Abdullatif A, Fauser S Ophthalmologe. 2020; 118(1):3-9.

PMID: 32666172 DOI: 10.1007/s00347-020-01173-8.

References

Garweg J, Tappeiner C, Halberstadt M . Pathophysiology of proliferative vitreoretinopathy in retinal detachment. Surv Ophthalmol. 2013; 58(4):321-9. DOI: 10.1016/j.survophthal.2012.12.004. View

Pastor J, Rodriguez de la Rua E, Martin F . Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. 2002; 21(1):127-44. DOI: 10.1016/s1350-9462(01)00023-4. View

Morales S, Mareninov S, Wadehra M, Zhang L, Goodglick L, Braun J . FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest Ophthalmol Vis Sci. 2008; 50(1):462-9. PMC: 3752991. DOI: 10.1167/iovs.07-1598. View

Forbes A, Wadehra M, Mareninov S, Morales S, Shimazaki K, Gordon L . The tetraspan protein EMP2 regulates expression of caveolin-1. J Biol Chem. 2007; 282(36):26542-51. DOI: 10.1074/jbc.M702117200. View

Wadehra M, Su H, Gordon L, Goodglick L, Braun J . The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death. Clin Immunol. 2003; 107(2):129-36. DOI: 10.1016/s1521-6616(03)00048-2. View

Morales S, Telander D, Mareninov S, Nagy A, Wadehra M, Braun J . Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells. Exp Eye Res. 2012; 102:10-6. PMC: 3432690. DOI: 10.1016/j.exer.2012.06.002. View

Hoffmann S, He S, Jin M, Ehren M, Wiedemann P, Ryan S . A selective cyclic integrin antagonist blocks the integrin receptors alphavbeta3 and alphavbeta5 and inhibits retinal pigment epithelium cell attachment, migration and invasion. BMC Ophthalmol. 2005; 5:16. PMC: 1184086. DOI: 10.1186/1471-2415-5-16. View

Remmele W, Schicketanz K . Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993; 189(8):862-6. DOI: 10.1016/S0344-0338(11)81095-2. View

ROBBINS S, Brem R, Wilson D, ORourke L, Robertson J, Westra I . Immunolocalization of integrins in proliferative retinal membranes. Invest Ophthalmol Vis Sci. 1994; 35(9):3475-85. View

10.

Asaria R, Charteris D . Proliferative vitreoretinopathy: developments in pathogenesis and treatment. Compr Ophthalmol Update. 2006; 7(4):179-85. View

11.

Wadehra M, Mainigi M, Morales S, Rao R, Gordon L, Williams C . Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod Biol Endocrinol. 2008; 6:15. PMC: 2329639. DOI: 10.1186/1477-7827-6-15. View

12.

Wadehra M, Goodglick L, Braun J . The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins. Mol Biol Cell. 2004; 15(5):2073-83. PMC: 404005. DOI: 10.1091/mbc.e03-07-0488. View

13.

Pastor J . Proliferative vitreoretinopathy: an overview. Surv Ophthalmol. 1998; 43(1):3-18. DOI: 10.1016/s0039-6257(98)00023-x. View

14.

Morales S, Mareninov S, Prasad P, Wadehra M, Braun J, Gordon L . Collagen gel contraction by ARPE-19 cells is mediated by a FAK-Src dependent pathway. Exp Eye Res. 2007; 85(6):790-8. DOI: 10.1016/j.exer.2007.08.014. View

15.

Wadehra M, Iyer R, Goodglick L, Braun J . The tetraspan protein epithelial membrane protein-2 interacts with beta1 integrins and regulates adhesion. J Biol Chem. 2002; 277(43):41094-100. DOI: 10.1074/jbc.M206868200. View

16.

Wadehra M, Sulur G, Braun J, Gordon L, Goodglick L . Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol. 2003; 74(2):106-12. DOI: 10.1016/s0014-4800(03)00009-1. View

17.

Telander D, Morales S, Mareninov S, Forward K, Gordon L . Epithelial membrane protein-2 (EMP2) and experimental proliferative vitreoretinopathy (PVR). Curr Eye Res. 2011; 36(6):546-52. PMC: 3931577. DOI: 10.3109/02713683.2011.561468. View

18.

Wang C, Wadehra M, Fisk B, Goodglick L, Braun J . Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood. 2001; 97(12):3890-5. DOI: 10.1182/blood.v97.12.3890. View

19.

Kroll P, Rodrigues E, Hoerle S . Pathogenesis and classification of proliferative diabetic vitreoretinopathy. Ophthalmologica. 2007; 221(2):78-94. DOI: 10.1159/000098253. View

20.

Zahn G, Volk K, Lewis G, Vossmeyer D, Stragies R, Heier J . Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachment. Invest Ophthalmol Vis Sci. 2009; 51(2):1028-35. DOI: 10.1167/iovs.09-3575. View